Liu Yanyan, Zhang Haodong, Zhang Wangli, Xiang Lanxin, Yin Zhucheng, Xu Hongli, Lu Ping, Ma Yifei, Xiong Lingyi, Zhang Xiangchen, Liang Xin, Luo Jing, Liang Xinjun
Division of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, 430030, Wuhan, Hubei, P. R. China.
School of life science and technology, Huazhong Agricultural University, 430070, Wuhan, Hubei, P. R. China.
Cell Death Discov. 2022 Apr 8;8(1):181. doi: 10.1038/s41420-022-00983-w.
Lung adenocarcinoma (LUAD) is a highly prevalent cancer with high mortality. Immune resistance and tumor metastasis are the pivotal factors for the promotion of LUAD. CircRNAs have been revealed a crucial pre-clinical diagnostic and therapeutic potentials in LUAD. Herein, we identify a novel circRNA (circ_0004140), derived from the oncogene YAP1, which is up-regulated in LUAD. The high expression of circ_0004140 is correlated with poor prognosis and CTL cells dysfunction in LUAD patients. Knockdown of circ_0004140 regulated LUAD cells proliferation, migration, and apoptosis. Mechanistically, circ_0004140 served as a sponge of miR-1184 targeting C-C motif chemokine ligand 22(CCL22). Overexpression of CCL22 reversed the inhibitory effect induced by si-circ_0004140 on cells proliferation and migration. Moreover, we also revealed that elevated circ_ooo4140 was related to cytotoxic lymphocyte exhaustion, and a combination therapy of C-021 (CCL22/CCR4 axis inhibitor) and anti-PD-1 attenuated LUAD promotion and immune resistance. In conclusion, circ_0004140 may drive resistance to anti-PD-1 immunotherapy, providing a novel potential therapeutic target for LUAD treatment.
肺腺癌(LUAD)是一种高发性癌症,死亡率很高。免疫抵抗和肿瘤转移是促进LUAD发展的关键因素。环状RNA(circRNAs)已被证明在LUAD中具有重要的临床前诊断和治疗潜力。在此,我们鉴定出一种源自癌基因YAP1的新型环状RNA(circ_0004140),其在LUAD中上调。circ_0004140的高表达与LUAD患者的不良预后和细胞毒性T淋巴细胞(CTL)功能障碍相关。敲低circ_0004140可调节LUAD细胞的增殖、迁移和凋亡。机制上,circ_0004140作为靶向C-C基序趋化因子配体22(CCL22)的miR-1184的海绵。CCL22的过表达逆转了si-circ_0004140对细胞增殖和迁移的抑制作用。此外,我们还发现circ_ooo4140升高与细胞毒性淋巴细胞耗竭有关,C-021(CCL22/CCR4轴抑制剂)和抗PD-1的联合治疗减弱了LUAD的进展和免疫抵抗。总之,circ_0004140可能驱动对抗PD-1免疫治疗的耐药性,为LUAD治疗提供了一个新的潜在治疗靶点。